CLENZIderm M — Class III drug recall D-0672-2017
Terminated recall by Valeant Pharmaceuticals North America LLC, reported 2017-04-26, distributed nationwide. Discoloration.
| Recall number | D-0672-2017 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Valeant Pharmaceuticals North America LLC, Bridgewater, NJ, United States |
| Recall initiated | 2017-03-20 |
| Classified | 2017-04-17 |
| Reported by FDA | 2017-04-26 |
| Terminated | 2019-06-14 |
| Distributed | Nationwide (US) |
| Quantity | 38,767 units |
| UPC / GTIN / UDI-DI | 00301876102042 |
| NDC | 00187-6102-04 |
| Lot numbers | 15J1277 |
| Expiration dates | 2017-04 |
Product
CLENZIderm M.D. Pore Therapy Salicylic Acid 2% Acne Treatment 5 fl. oz. (148 mL), Valeant Pharmaceuticals North America LLC Distributed by OMP, Inc Long Beach, CA 90806 Made in USA. Product SKU 301876102042, NDC 0187-6102-04
Reason for recall
Discoloration.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0672-2017. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.